Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies.

Watanabe, Shohei; Yoshizumi, Kazuki; Moriguchi, Sayaka; Higashiyama, Tomoki; Negi, Yoshiki; Mikami, Koji; Kimura, Takashi.

Afiliação

Watanabe S; Department of Neurology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Yoshizumi K; Department of Neurology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Moriguchi S; Department of Neurology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Higashiyama T; Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Negi Y; Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Mikami K; Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Kimura T; Department of Neurology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.

eNeurologicalSci ; 25: 100386, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34926841